-

Aetna Approves Coverage for Cleerly's AI Cardiovascular Imaging Analysis

Major Insurer Joins UnitedHealthcare, Cigna, and Humana in Covering Cleerly's AI-QCT Technology as Industry Momentum Builds with 86+ Million Lives Now Covered

DENVER--(BUSINESS WIRE)--Cleerly, a leader in AI-based cardiovascular imaging, today announced that Aetna will begin covering Cleerly® LABS plaque analysis effective immediately. Aetna, which covers more than 20+ million lives, joins UnitedHealthcare, Cigna, Humana, BCBS Kansas City, Excellus BCBS, and EviCore in providing coverage for this advanced technology.

Following Medicare's 2024 coverage decision and the technology's approval for a CPT® I code effective January 1, 2026, major commercial payors representing over 86+ million Americans now support AI-QCT coverage.

Share

Cleerly LABS is an interactive analysis software that leverages AI/ML-based advanced plaque analysis to identify, characterize, and quantify coronary artery plaque and stenosis, supporting visualization and measurement of coronary arteries in patients with known or suspected coronary artery disease (CAD).

This milestone reflects the rapid industry adoption of Artificial Intelligence Enabled CT-Based Quantitative Coronary Tomography (AI-QCT)/Coronary Plaque Analysis (AI-CPA) in cardiovascular care. Following Medicare's 2024 coverage decision and the technology's approval for a CPT® I code effective January 1, 2026, major commercial payors representing over 86+ million Americans now support AI-QCT/AI-CPA coverage.

Coverage Criteria

CCTA plaque quantification or coronary plaque analysis using data from CCTA when all of the following criteria are met:

  1. The plaque quantification and/or analysis platform has been FDA-cleared; and
  2. The member has acute or stable chest pain with no known coronary artery disease (CAD); and
  3. The member has had a current CCTA and the results indicate any of the following risk categories; Note: CCTA plaque quantification or coronary plaque analysis is not indicated for CAD-RAD 4, 5, and/or N; see Appendix for category definitions:
    1. Intermediate risk
    2. CAD-RADS 1
    3. CAD-RADS 2
    4. CAD-RADS 3; and
  4. Physical examination and other cardiac testing (e.g., electrocardiogram, laboratory testing) are negative or inconclusive for acute coronary syndrome

"We're seeing unprecedented payor acceptance of AI-powered cardiovascular imaging," said James K. Min, MD, founder and CEO of Cleerly. "Major insurers, covering over 86 million lives, now recognize that AI-QCT delivers better patient outcomes while reducing costs. This is a fundamental shift in how we approach cardiac care."

This growing payor support reflects increasing clinical evidence that AI-QCT/AI-CPA supports the assessment of coronary artery disease by enhancing diagnostic evaluation and enabling efficient use of healthcare resources. These advances are critical for addressing cardiovascular disease, the leading cause of death in the United States.

Visit www.cleerlyhealth.com to learn more.

About Cleerly

Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly’s approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com.

Contacts

Cleerly Media Contact
Christy Sievert
press@cleerlyhealth.com

More News From Cleerly

PARAMOUNT, the First Randomized Trial of AI-Enabled Plaque-Based Care, Meets Primary Endpoint in Late-Breaking Results at AHA 2026

DENVER--(BUSINESS WIRE)--Cleerly, a leader in advanced cardiovascular imaging analysis, today presented primary results from PARAMOUNT, the first randomized trial of AI-QCT-guided care against usual care, as Late-Breaking Science at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago. Compared with usual care based on stress testing, care guided by AI-based quantitative coronary CT analysis (AI-QCT) improved diagnostic certainty and led to more patients receiving lipid-lowe...

Cleerly to Present Late-Breaking Results from the First Randomized Trial of AI-QCT-Guided Care in Patients with Stable Chest Pain at AHA 2026

DENVER--(BUSINESS WIRE)--Cleerly, a leader in AI-based cardiovascular imaging, announces its participation in the American Heart Association (AHA) Scientific Sessions 2026, November 6 to 9 at McCormick Place Convention Center in Chicago, Illinois. Cleerly will share primary results from PARAMOUNT, the first randomized trial to compare personalized care guided by AI-based quantitative coronary CT analysis (AI-QCT) with usual care in symptomatic patients with suspected coronary artery disease (CA...

Cleerly's TRANSFORM Trial Sends a Mobile CT Scanner Across the South to Reach Patients in Underserved Communities

DENVER--(BUSINESS WIRE)--Cleerly, a leader in advanced cardiovascular imaging analysis, and Clear Heart and Lung Imaging, a leader in outpatient imaging care, have taken a cardiac-capable mobile CT scanner across the southern United States to expand access to cardiovascular research and enable communities and clinics to participate in Cleerly's TRANSFORM Trial. From July through September 2026, the CT scanner traveled through Arizona, Louisiana, Georgia, and Florida, bringing cardiovascular ima...
Back to Newsroom